Skip to main content

Press releases

Go back

Galimedix Therapeutics announces new pre-clinical data with GAL-201 in an Alzheimer’s disease transgenic model to be presented at AD/PD™ 2024 Conference

Galimedix Appoints Dr. Luciana Summo as Vice President, R&D Operations

Théa Open Innovation and Galimedix announce strategic partnership to develop and commercialize GAL-101, a Phase 2/3-ready small molecule, to treat ophthalmic indications with high unmet medical need

Galimedix Accelerating Development of Its Next-Generation Oral Anti-Amyloid Beta Drug GAL-201 for Alzheimer’s Disease

Planned Phase 2 Trial of Visual Function Improvement in iAMD Gains Support From Novel Analysis Of Microperimetry Endpoints

Galimedix Therapeutics, Inc.’s GAL-101 Gains from Target Validation by Positive Phase 3 Results of Biogen’s Aducanumab

Galimedix Therapeutics, Inc. Appoints Recognized Industry Veteran, Alexander Gebauer, M.D., Ph.D., as Executive Chairman

Galimedix Therapeutics, Inc. To Present at the BIO Investor Summit

Galimedix Therapeutics, Inc. To Present at Ophthalmology Innovation Summit During the American Academy of Ophthalmology Meeting

Preclinical Studies Demonstrate Galimedix Therapeutics’ Investigational Compound GAL-101 Shows Neuroprotective Effect from Toxic Amyloid-Beta in Dry AMD and Glaucoma Models

1
2
3